- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
PSS World Medical buys Medical Imaging
PSS World Medical continues its aggressive acquisition drive. The medical supplies distributor this month announced that it will purchase Medical Imaging Services of Little Rock, AR, a private medical imaging distributor with annual revenues of
PSS World Medical continues its aggressive acquisition drive. The medical supplies distributor this month announced that it will purchase Medical Imaging Services of Little Rock, AR, a private medical imaging distributor with annual revenues of approximately $18 million. The agreement solidifies PSS World's operations in the southwest and south central U.S. and adds to two other recent acquisitions in the region (SCAN 2/18/98).
In other news, the Jacksonville, FL, company this month signed an agreement with SonoSight for exclusive U.S. rights to distribute SonoSight's handheld ultrasound products to private physicians' offices. The deal gives SonoSight access to this market, while PSS World improves the range of medical techology it can offer. In May, SonoSight received 510(k) approval from the Food and Drug Administration for its first handheld ultrasound device, which it plans to release in the second half of 1999.
New Meta-Analysis Examines MRI Assessment for Treatment of Esophageal Cancer
September 12th 2024Diffusion-weighted MRI provided pooled sensitivity and specificity rates of 82 percent and 81 percent respectively for gauging patient response to concurrent chemoradiotherapy for esophageal cancer, according to new meta-analysis.
Study for Emerging PET/CT Agent Reveals ‘New Standard’ for Detecting Clear Cell Renal Cell Carcinoma
September 11th 2024Results from a multicenter phase 3 trial showed that the PET/CT imaging agent (89Zr)Zr-girentuximab had an 85.5 percent mean sensitivity rate for the diagnosis of clear cell renal cell carcinoma.
Researchers Show Higher Breast Cancer Upstaging Rate with 18F-FAPI PET/CT
September 9th 2024The imaging agent 18F-FAPI PET/CT demonstrated greater than a 45 percent higher sensitivity rate in comparison to 18F-FDG PET/CT for the detection of axillary and extraaxillary regional lymph node metastases, according to a lesion-based analysis from a recent study.
